MetaCap

iBio (IBIO) vs Tenax Therapeutics (TENX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

iBio (IBIO) has outperformed Tenax Therapeutics (TENX) over the past year, losing 23.8% versus a loss of 84.7%. Over five years, IBIO leads with a -99.8% price change compared with -99.9% for TENX. Tenax Therapeutics is the larger company by market cap ($56.9 million vs $56.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IBIO-23.80%TENX-84.66%
+206%+54%-99%
Nov 21, 20251 yearNov 20, 2026
IBIO-99.76%TENX-99.94%
+7%-49%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IBIO versus TENX key metrics
MetricIBIOTENX
Share price$0.8001$1.25
Market cap$56.37M$56.92M
1-day change-0.11%-10.07%
YTD return-58.54%-89.75%
1-year return-23.80%-84.66%
5-year return-99.76%-99.94%
EPS (TTM)$-0.27$-1.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$100.00K$0
Revenue growth (YoY)-75.00%—
Net income (latest FY)$-33.04M$-52.60M
Operating margin-35141.00%—
Net margin-33044.00%—
52-week high$3.82$19.40
52-week low$0.68$1.24
Distance from 52-week high-79.05%-93.56%
Analyst consensusstrong_buynone
Avg. price target upside+611.16%+904.80%
Average volume678.91K3.15M
Shares outstanding70.46M45.54M
Employees2314
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IBIO has outperformed TENX by 60.9 percentage points over the past year.

About iBio

IBIO stock →

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

About Tenax Therapeutics

TENX stock →

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

IBIO vs TENX FAQ

Which is bigger, iBio or Tenax Therapeutics?

Tenax Therapeutics (TENX) is larger, with a market capitalization of $56.92M compared with $56.37M for iBio (IBIO).

Which stock has performed better over the past year, IBIO or TENX?

IBIO returned -23.80% over the past 12 months, compared with -84.66% for TENX (price return, excluding dividends). Past performance does not predict future results.

Are iBio and Tenax Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons